Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 27, 2020 (6 years ago)

Topiramate 25mg Tabs White/round tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Topiramate 25mg Tabs White/round tablets, 10-count bags, Distributed by: Calvin Scott & Co., Inc. Alb., MN 87123, Mfg: Sun Pharm., Inc. Cranbury, NJ 08512, NDC 47335-0707-13

Affected NDC 47335-0707-13

Compare with the code on your package — it is the most precise check available.

Drug: Topiramate

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Topiramate
NDC 47335-0707
25 mg/1 Tablet, Film Coated
Oral
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Calvin Scott & Company, Inc.
NDC code
47335-0707-13
Origin
NM, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1520-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Topiramate recalls

See all
Class III · Low risk

Trokendi XR

Failed dissolution specifications.

Ongoing Dissolution failure Supernus Pharmaceuticals, Inc. NDC 17772-102-30 D-0833-2026
Class III · Low risk

Trokendi XR

Failed Dissolution Specifications

Ongoing Dissolution failure Supernus Pharmaceuticals, Inc. NDC 17772-101-30 D-0758-2026
Class III · Low risk

Eprontia (topiramate)

Failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months.

Terminated Impurity / degradation Azurity Pharmaceuticals, Inc. NDC 52652-9001-1 D-0213-2024
Class II · Moderate risk

Trokendi XR

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Terminated Temperature excursion Cardinal Health Inc. NDC 17772-103-30 D-0570-2021

Other recalls by Calvin Scott & Company, Inc.

All 2020 recalls
Class I · High risk

Benzonatate capsules

Labeling: Label Mix-up: Bottle labeled as Benzonatate 100 mg capsules contained Benzphetamine 50 mg tablets and a bottle labeled as Benzphetamine 50 mg tablets contained Benzonatate 100 mg capsules.

Terminated Labeling / mix-up Calvin Scott & Company, Inc. NDC 67877-0573-05 D-1124-2022
Class III · Low risk

Benzphetamine tablets

Labeling: Label Mix-up: Bottle labeled as Benzonatate 100 mg capsules contained Benzphetamine 50 mg tablets and a bottle labeled as Benzphetamine 50 mg tablets contained Benzonatate 100 mg capsules.

Terminated Labeling / mix-up Calvin Scott & Company, Inc. NDC 10702-0040-50 D-1123-2022
Class II · Moderate risk

Phentermine

cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.

Terminated Stability / shelf life Calvin Scott & Company, Inc. NDC 00527-0597-10 D-0011-2021
Class II · Moderate risk

Diethylpropion

cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.

Terminated Stability / shelf life Calvin Scott & Company, Inc. NDC 00527-1477-01 D-0010-2021